Zhongtian Qi

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Wanda Tang

Naval University of Engineering

Xu Zheng

Institute of Infection and Immunity

Xijing Qian

Second Military Medical University

Haoran Peng

Naval University of Engineering

Cuiling Ding

Naval University of Engineering

Yan Liu

Imperial College London

Bingan Wu

Second Military Medical University

Ping Zhao

China Medical University

Yangang Liu

Naval University of Engineering

Hailin Tang

Naval University of Engineering

Cooperative Institutions

Naval University of Engineering

Second Military Medical University

Central South University

Chinese Academy of Medical Sciences & Peking Union Medical College

Changhai Hospital

Army Medical University

China Medical University

Southern Medical University

Shandong University of Traditional Chinese Medicine

Union Hospital

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Buparvaquone Inhibits Severe Fever with Thrombocytopenia Syndrome Virus Infection Via Interacting with Viral Glycoprotein Gc

Bingan Wu Chenyang Yu Xuewei Sun Yangang Liu Wanda Tang

10.2139/ssrn.5016433

Cite

Citations (0)

Recent research advances in the development of Dabie Banda virus vaccines

PLoS neglected tropical diseases (2024)

Chenyang Yu Yuxiang Lin Yixin Dai Bingan Wu Zhongtian Qi

Severe fever with thrombocytopenia syndrome (SFTS) is a newly identified tick-borne viral hemorrhagic fever caused by Dabie Banda virus (DBV). The virus was first discovered in eastern China in 2009 and is now considered an infectious disease with a mortality rate ranging from 6.3% to 30%. The best strategy for controlling SFTS is to develop effective vaccines. However, no approved vaccines are currently available to prevent this disease, despite the number of extensive and in-depth studies conducted on DBV in the past few years. This review focuses on the structure of DBV and the induced host immune responses which are the fundamental factors in vaccine development, and thoroughly summarizes the current research progress on DBV vaccines. The developing DBV vaccines include protein subunit vaccines, live attenuated vaccines, recombinant virus vector vaccines, and DNA vaccines. At present, almost all candidate vaccines for DBV are in the laboratory development or preclinical stages. There remain challenges in successfully developing clinically approved DBV vaccines.

Attenuated vaccine

10.1371/journal.pntd.0012411

Cite

Citations (0)

Antiviral efficacy of selective estrogen receptor modulators against SARS‐CoV‐2 infection in vitro and in vivo reveals bazedoxifene acetate as an entry inhibitor

Journal of Medical Virology (2022)

Miao Gen Haoran Peng Hailin Tang Yangang Liu Xu Zheng

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the seventh member of the coronavirus family that can infect humans. Recently, more contagious and pathogenic variants of SARS-CoV-2 have been continuously emerging. Clinical candidates with high efficacy and ready availability are still in urgent need. To identify potent anti-SARS-CoV-2 repurposing drugs, we evaluated the antiviral efficacy of 18 selective estrogen receptor modulators (SERMs) against SARS-CoV-2 infection. Six SERMs exhibited excellent anti-SARS-CoV-2 effects in Vero E6 cells and three human cell lines. Clomifene citrate, tamoxifen, toremifene citrate, and bazedoxifene acetate reduced the weight loss of hamsters challenged with SARS-CoV-2, and reduced hamster pulmonary viral load and interleukin-6 expression when assayed at 4 days postinfection. In particular, bazedoxifene acetate was identified to act on the penetration stage of the postattachment step via altering cholesterol distribution and endosome acidification. And, bazedoxifene acetate inhibited pseudoviruses infection of original SARS-CoV-2, Delta variant, Omicron variant, and SARS-CoV. These results offer critical information supporting bazedoxifene acetate as a promising agent against coronaviruses.

Toremifene

Vero cell

10.1002/jmv.27951

Cite

Citations (9)

High-Throughput Screening of FDA-Approved Drug Library Reveals Ixazomib Is a Broad-Spectrum Antiviral Agent against Arboviruses

Viruses (2022)

Cuiling Ding Wanda Tang Binghui Xia Haoran Peng Yan Liu

The emergence of significant arboviruses and their spillover transmission to humans represent a major threat to global public health. No approved drugs are available for the treatment of significant arboviruses in circulation today. The repurposing of clinically approved drugs is one of the most rapid and promising strategies in the identification of effective treatments for diseases caused by arboviruses. Here, we screened small-molecule compounds with anti-tick-borne encephalitis virus, West Nile virus, yellow fever virus and chikungunya virus activity from 2580 FDA-approved drugs. In total, 60 compounds showed antiviral efficacy against all four of the arboviruses in Huh7 cells. Among these compounds, ixazomib and ixazomib citrate (inhibitors of 20S proteasome β5) exerted antiviral effects at a low-micromolar concentration. The time-of-drug-addition assay suggested that ixazomib and ixazomib citrate disturbed multiple processes in viruses' life cycles. Furthermore, ixazomib and ixazomib citrate potently inhibited chikungunya virus replication and relieved virus-induced footpad swelling in a mouse model. These results offer critical information which supports the role of ixazomib as a broad-spectrum agent against arboviruses.

Broad spectrum

Approved drug

Ixazomib

10.3390/v14071381

Cite

Citations (8)